Glancy Prongay & Murray LLP Commences Investigation on Behalf of Spectrum Pharmaceuticals, Inc. Investors
September 21 2016 - 2:24PM
Business Wire
Glancy Prongay & Murray LLP (“GPM”) announces an
investigation on behalf of Spectrum Pharmaceuticals, Inc.
(“Spectrum” or the “Company”) (NASDAQ: SPPI) concerning the Company
and its officers’ possible violations of federal securities
laws.
The investigation concerns whether the Company misled investors
regarding the FDA’s inquiry into whether data from the Spectrum 611
and 612 Studies were clinically meaningful; and whether the FDA
advised defendants in December 2012 not to submit the New Drug
Application based on data from the 611 and 612 Studies. Following
the Company’s announcement that the FDA had denied approval for its
apaziquone NDA the Company’s shares fell sharply in value.
If you purchased Spectrum securities, have information or would
like to learn more about these claims, or have any questions
concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire,
of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California
90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to
shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com. If you inquire by email please include
your mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160921006419/en/
Glancy Prongay & Murray LLP, Los Angeles/New YorkLesley
Portnoy, 310-201-9150 or
888-773-9224shareholders@glancylaw.comwww.glancylaw.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Sep 2023 to Sep 2024